DNA Aneuploidy, S-phase fraction, nuclear p53 positivity, and survival in non-small-cell lung carcinoma

Virchows Archiv

Volumn 431, Issue 3, 1997, Pages 173-179

  Dalquen, Peter ^a   Moch, Holger ^a   Feichter, Georg ^a   Lehmann, M ^a   Solèr, Markus ^a   Stulz, Peter ^a   Jordan, Paul ^a   Torhorst, Joachim ^a   Mihatsch, Michael J ^a   Sauter, Guido ^a  

^a UNIVERSITY OF BASEL   (Switzerland)

Author keywords

DNA aneuploidy; Non small cell lung cancer; Prognosis; S phase fraction p53 nuclear overexpression

Indexed keywords

PROTEIN P53;

ANEUPLOIDY; ARTICLE; CANCER SURGERY; CANCER SURVIVAL; CELL CYCLE S PHASE; CELL PROLIFERATION; FLOW CYTOMETRY; FOLLOW UP; GENETIC STABILITY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG NON SMALL CELL CANCER; LUNG RESECTION; MAJOR CLINICAL STUDY; MULTIVARIATE ANALYSIS; PLOIDY; PRIORITY JOURNAL; PROGNOSIS;

ANEUPLOIDY; CARCINOMA, NON-SMALL-CELL LUNG; CELL NUCLEUS; FLOW CYTOMETRY; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; PROGNOSIS; S PHASE; SURVIVAL RATE; TUMOR SUPPRESSOR PROTEIN P53;

EID: 9844241593     PISSN: 09456317     EISSN: None     Source Type: Journal    
DOI: 10.1007/s004280050085     Document Type: Article

References (50)

1. Carey FA, Fabbroni G, Lamb D (1992) Expression of proliferating cell nuclear antigen in lung cancer: a systematic study and correlation with DNA ploidy (see comments). Histopathology 20:499-503
2. Cibas ES, Melamed MR, Zaman ME, Kimmel M (1989) The effect of tumour size and tumour cell DNA content on the survival of patients with with stage I adenocarcinoma of the lung. Cancer 63:1552-1556
3. Dalquen P, Sauter G, Torhorst JES, Jordan P, Lehmann S, Solèr M, Stulz P, Mihatsch MM, Gudat F (1996) Nuclear p53 overexpression is an independent prognostic parameter in node negative non small cell lung carcinoma. J Pathol (Lond) 178:53-58
4. Dazzi H, Thatcher N, Hasleton PS, Swindell R (1990) DNA analysis by flow cytometry in non-small cell lung cancer: relationship to epidermal growth factor receptor, histology, tumour stage, and survival. Respir Med 84:217-223
5. Dillman RO, Berry C, Ryan KP, Green MR, Seagren SL (1991) Recent outcomes for patients with carcinoma of the lung. Cancer Invest 9:9-17
6. Ebina M, Steinberg SM, Mulshine JL, Linnoila RI (1994) Relationship of p53 overexpression and up-regulation of proliferating cell nuclear antigen with the clinical course of non-small cell lung cancer. Cancer Res 54:2496-2503
7. Finlay C, Hinds P, Tan T, Eliyahu D, Oren M, Levine A (1988) Activating mutations for transformation by p53 produce a gene product that forms an hsc70-p53 complex with an altered half-life. Mol Cell Biol 8:531-539
8. Fontanini G, Pingitore R, Bigini D, Vignati S, Pepe S, Ruggero A, Macchiarini P (1992) Growth fraction in non-small cell lung cancer estimated by proliferating cell nuclear antigen and comparison with Ki-67 labeling and DNA flow cytometry data. Am J Pathol 141:1285-1290
9. Giaretti W (1994) A model of DNA aneuploidization and evolution in colorectal cancer. Lab Invest 71:904-910
10. Hasse J (1986) Surgical treatment of bronchial carcinoma, sreening methods, early and late results. Springer, Berlin Heidelberg New York Tokyo
11. Hermanek P, Scheibe O, Spiessl B, Wagner G (1992) TNM Klassifikation maligner Tumoren, pp 80-82. Springer for UICC, Berlin Heidelberg New York
12. Hollstein M, Sidransky D, Vogelstein B, Harris CC (1991) p53 mutations in human cancers. Science 253:49-53
13. Ishida T, Kaneko S, Akazawa K, Tateishi M, Sugio K, Sugimachi K (1993) Proliferating cell nuclear antigen expression and argyrophilic nucleolar organizer regions as factors influencing prognosis of surgically treated lung cancer patients. Cancer Res 53:5000-5003
14. Isobe H, Miyamoto H, Inoue K, Shimizu M, Endo T, Mizuno S, Kawakami Y (1990) Flow cytometric DNA content analysis in primary lung Cancer: comparison of results from fresh and paraffin-embedded specimens. J Surg Oncol 43:36-39
15. Isobe H, Miyamoto H, Shimizu T, Haneda H, Hashimoto M, Inoue K, Mizuno S, Kawakami Y (1990) Prognostic and therapeutic significance of the flow cytometric nuclear DNA content in non-small cell lung cancer. Cancer 65:1391-1395
16. Kearsley J, Furlong R, Cooke R, Waters M (1990) An immunohistochemical assessment of cellular proliferation markers in head and neck squamous cell cancers. Br J Cancer 61:821-827
17. Lane DP (1992) p53, guardian of the genome. Nature 358:15-16
18. Leoncini L, Sforza V, Lavarini E, Nuti S, Gotti G, Tosi P (1988) Flow-cytometric assessment of DNA index and percent S phase cells in bronchogenic epidermoid carcinoma. Appl Pathol 6:28-34
19. Merkel DE, McGuire WL (1990) Ploidy, proliferative activity and prognosis. DNA flow cytometry of solid tumours. Cancer 65:1194-1205
20. Miyamoto H, Harada M, Isobe H, Akita HD, Haneda H, Yamaguchi E, Kuzumaki N, Kawakami Y (1991) Prognostic value of nuclear DNA content and expression of the ras oncogene product in lung cancer. Cancer Res 51:6346-6350
21. Moch H, Sauter G, Mihatsch MJ, Gudat F, Epper R, Waldman FM (1994) p53 but not erbB-2 expression is associated with rapid tumour proliferation in urinary bladder cancer. Hum Pathol 25:1346-1351
22. Morkve O, Halvorsen OJ, Skjaerven R, Stangeland L, Gulsvik A, Laerum OD (1993) Prognostic significance of p53 protein expression and DNA ploidy in surgically treated non-small cell lung carcinomas. Anticancer Res 13:571-578
23. Mountain CF (1991) Surgical treatment of lung cancer. Rev Oncol Hematol 11:179-207
24. Ogawa J, Tsurumi T, Yamada S, Koide S, Shohtsu A (1994) Blood vessel invasion and expression of sialyl Lewisx and pro- liferating cell nuclear antigen in stage I non-small cell lung cancer. Relation to postoperative recurrence. Cancer 73:1177-1183
25. Pence JC, Kerns BJ, Dodge RK, Iglehart JD (1993) Prognostic- significance of the proliferation index in surgically resected non-small-cell lung cancer. Arch Surg 128:1382-1390
26. Rice TW, Bauer TW, Gephardt GN, Medendorp SV, McLain DA, Kirby TJ (1993) Prognostic significance of flow cytometry in non-small-cell lung cancer. J Thorac Cardiovasc Surg 106:210-217
27. Sahin AA, Ro JY, El NAK, Lee JS, Ayala AG, Teague K, Hong WK (1990) Flow cytometric analysis of the DNA content of non-small cell lung cancer. Cancer 65:530-537
28. Sahin AA, Ro J, Ro JY, Blick MB, El-Naggar AK, Ordonez NG, Fritsche HA, Smith HL, Hortobagyi GN, Ayala AG (1991) Ki-67 immunostaining in node-negative stage I/II breast carcinoma. Significant correlation with prognosis. Cancer 68:549-557
29. Sauter G, Deng G, Moch H, Kerschmann R, Matsumura K, DeVries S, George T, Fuentes J, Carroll P, Mihatsch M, Waldman F (1994) Physical deletion of the p53 gene in bladder cancer: detection by fluorescence in situ hybridization. Am J Pathol 144:756-766
30. Sauter G, Haley J, Chew K, Kerschmann R, Moore D, Carroll P, Moch H, Gudat F, Mihatsch M, Waldman F (1994) Epidermal growth factor receptor expression is associated with rapid tumour proliferation in bladder cancer. Int J Cancer 57:508-514
31. Schirren J, Krysa S, Trainer S, Drings P, Vogt-Moykopf I (1995) Carcinoma of the lung: surgical treatment and results, pp 212-240. (European respiratory monographs, vol 1) European Respiratory Society Journals, Lund
32. Schmidt RA, Rusch VW, Piantadosi S (1992) A flow cytometric study of non-small cell lung cancer classified as T1NO. Cancer 69:78-85
33. Stipa S, Danesi DT, Modini C, Cicconetti F, Mauro F, Schillaci A, Mecozzi A, Nicolanti V, Stipa F, Mancini M, Bangrazi C, Botti C (1993) The importance of heterogeneity and of multiple site sampling in the prospective determination of deoxyribonucleic acid flow cytometry. Surg Gynecol Obstet 176:427-434
34. Ten Velde GPM, Schutte B, Vermeulen A, Volovics A, Reynders MMJ, Blijham GH (1988) Flow cytometric analysis of DNA ploidy level in paraffin-embedded tissue of non-small- cell lung cancer. Eur J Cancer Clin Oncol 24:455-460
35. Teodori L, Trinca ML, Goehde W, Hemmer J, Salvati F, Storniello G, Mauro F (1990) Cytokinetic investigation of lung tumours using the anti-bromodeoxyuridine (BUdR) monoclonal antibody method: comparison with DNA flow cytometric data. Int J Cancer 45:995-1001
36. Theunissen PHMH, Leers MPG, Bollen ECM (1992) Proliferating cell nuclear antigen (PCNA) expression in formalin- fixed tissue of non-small cell lung carcinoma. Histopathology 20:251-255
37. Tirindelli-Danesi D, Teodori L, Mauro F et al (1987) Prognostic significance of flow cytometry in lung cancer. Cancer 60:844-851
38. Toi M, Nakamura T, Mukaida H, Wada T, Osaki A, Yamada H, Toge T, Niimoto M, Hattori T (1990) Relationship between epidermal growth factor receptor status and various prognostic factors in human breast cancer. Cancer 65:1980-1984
39. Tribukait B (1987) Flow cytometry in assessing the clinical aggressivenessof genito-urinary neoplasms. World J Urol 5:108-122
40. Tubiana M, Courdi A (1989) Cell proliferation kinetics in human solid tumours: relation to probability of metastatic dissemination and long-term survival. Radiother Oncol 15:1-18
41. Tungekar MF, Gatter KC, Dunnill MS, Mason DY (1991) Ki- 67 immunostaining and survival in operable lung cancer. Histopathology 19:545-550
42. Van Bodegom PC, Baak JPA, Stroet VGC, Schipper NW, Wisse BECM, Vanderschueren RGJRA, Wagenaar SS (1989) The percentage of aneuploid cells is significantly correlated with survival in accurately staged patients with stage I resected squamous cell lung cancer and long-term follow up. Cancer 63:143-147
43. Visakorpi T, Kallioniemi OP, Heikkinen A, Koivula T, Isola J (1992) Small subgroup of aggressive, highly proliferative prostatic carcinomas defined by p53 accumulation. J Natl Cancer Inst 84:883-887
44. Vogelstein B, Kinzler KW (1992) p53 function and dysfunction. Cell 70:523-526
45. Volm M, Drings P, Mattern J, et al (1985) Prognostic significance of DNA patterns and resistance-predictive tests in non- small cell lung carcinoma. Cancer 56:1396-1403
46. Volm M, Bak M, Hahn EW, Mattern J, Weber E (1988) DNA and S-phase distribution and incidence of metastasis in human primary lung carcinoma. Cytometry 9:183-188
47. Volm M, Mattern J, Muller T, Drings P (1988) Flow cytometry of epidermoid lung carcinomas: Relationship of ploidy and cell cycle phases to survival. A five-year follow up study. Anticancer Res 8:105-112
48. Volm M, Mattern J, Müller T, Vogt-Moykopf I (1988) Flow cytometry in human adenocarcinoma of the lung: prognostic significance for survival. Tumor Diagn Ther 9:177-181
49. The World Health Organization (1981) Histologic typing of lung cancer. Chest 89:1595-1602
50. Zimmermann PV, Hanson GAT, Bent MH, Parsons PC (1987) Ploidy as a prognostic determinant in surgically treated lung cancer. Lancet II:530-533